Fulcrum Therapeutics’ (FULC) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock.

Other equities research analysts also recently issued research reports about the stock. Bank of America downgraded shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $10.00 to $2.00 in a research report on Thursday, September 12th. Cantor Fitzgerald cut Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a report on Thursday, September 12th. Leerink Partners reaffirmed a “market perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Thursday, September 12th. Royal Bank of Canada downgraded Fulcrum Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their target price for the company from $15.00 to $4.00 in a report on Thursday, September 12th. Finally, Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and lowered their price target for the stock from $22.00 to $3.00 in a research note on Thursday, September 12th. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $9.33.

Fulcrum Therapeutics Stock Performance

Shares of Fulcrum Therapeutics stock opened at $3.01 on Thursday. Fulcrum Therapeutics has a one year low of $2.87 and a one year high of $13.70. The company has a market cap of $162.36 million, a P/E ratio of -9.71 and a beta of 2.24. The firm has a fifty day moving average of $3.75 and a two-hundred day moving average of $6.47.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. National Bank of Canada FI raised its position in Fulcrum Therapeutics by 869.6% during the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after acquiring an additional 4,000 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Fulcrum Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Fulcrum Therapeutics by 26.5% during the 3rd quarter. SG Americas Securities LLC now owns 33,019 shares of the company’s stock worth $118,000 after purchasing an additional 6,926 shares during the last quarter. Profund Advisors LLC purchased a new stake in Fulcrum Therapeutics in the 2nd quarter valued at approximately $68,000. Finally, American Century Companies Inc. grew its holdings in Fulcrum Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 104,371 shares of the company’s stock valued at $647,000 after buying an additional 12,167 shares during the last quarter. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.